| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
See Remarks
1 company
Farrow Jeffrey S is a See Remarks at TARS. Recent filings cover 0 purchases and 9 sales. Those positions are worth an estimated $3.5M at current prices.
Our model assigns Farrow Jeffrey S a below-average insider score of 33/100, based on 5 past trades. Over a 12-month horizon, 0.0% of those trades were profitable, with an average 12-month return of -43.9%.
Farrow Jeffrey S's largest disclosed position is in TARS as See Remarks, worth about $3.5M. The recent filings there lean toward selling, a net 48,603 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | TARS Tarsus Pharmaceuticals, Inc. | See Remarks | Sale+OE | 14,396 | $60.95 | $877,436.20 | -20.2% | +31.5% | - | |
| Mar 19, 2026 | TARS Tarsus Pharmaceuticals, Inc. | See Remarks | Sell | 6,430 | $68.36 | $439,566.05 | -12.9% | -6.3% | - | |
| Jun 17, 2025 | TARS Tarsus Pharmaceuticals, Inc. | See Remarks | Sale+OE | 13,608 | $40.42 | $550,035.36 | -27.0% | +25.8% | +57.2% | |
| Mar 20, 2025 | TARS Tarsus Pharmaceuticals, Inc. | See Remarks | Sell | 3,724 | $47.88 | $178,306.42 | -14.2% | -17.7% | +29.3% | |
| Jun 18, 2024 | TARS Tarsus Pharmaceuticals, Inc. | See Remarks | Sale+OE | 10,445 | $27.47 | $286,924.15 | -36.5% | +16.9% | +50.5% |